Update on the Scottish Medicines Consortium's Assessment of Nusinersen
30 November 2017
We have now received a further update and clarification that the Scottish Medicines Consortium will be assessing nusinersen for:
"pre-symptomatic infantile-onset and later-onset 5q SMA, but not for before birth or Adult Onset SMA".
This means they will be considering the case for SMA Types 1, 2, and 3 only.
SMA Support UK, Muscular Dystrophy UK and the SMA Trust have each been invited to provide a Patient Group Submission by 5th February 2018.
We will be in touch with individuals and families affected by SMA who live in Scotland, and TreatSMA for their input.